Compare MPLT & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | CLVT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United Kingdom |
| Employees | 133 | 12000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | MPLT | CLVT |
|---|---|---|
| Price | $36.90 | $2.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | ★ $32.67 | $3.22 |
| AVG Volume (30 Days) | 563.2K | ★ 9.1M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.24 | $1.66 |
| 52 Week High | $40.43 | $4.77 |
| Indicator | MPLT | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 42.54 |
| Support Level | $26.20 | $1.90 |
| Resistance Level | $40.43 | $2.65 |
| Average True Range (ATR) | 2.75 | 0.18 |
| MACD | -0.46 | -0.03 |
| Stochastic Oscillator | 35.78 | 31.29 |
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.